Jenna Payesko

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the current state and future of Hepatitis C.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the challenges treating co-infected HIV and HCV patients.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the impact and potential for antivirals in the US.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, discusses Candida auris.

Paul Ananth Tambyah, MD, Dept. of Medicine, Infectious Disease, National University of Singapore, provides an overview of infection control approach for travelers with either epidemic or endemic diseases from various parts of the world.

Researchers work showed how misalignment between a person’s lifestyle and the biological clock could affect well-being and contribute to the risks for various diseases.

James Underberg, MD, President-Elect of the National Lipid Association, Clinical Assistant Professor of Medicine, NYU School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, discusses statin intolerance and the future of cholesterol treatments.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

This is potentially the first therapy seeking FDA-approval utilizing human gut microbiome.

First-in-class antibody demonstrates significant reduction in bullous pemphigoid activity.

The study is among the first to provide scientific evidence for medication-free approach to condition.

APTIOM provides an important new treatment option for partial-onset seizures in pediatric patients ages 4 and up for adjunctive and monotherapy use.

Development of surotomycin has been discontinued based on trial results.

At 24 weeks, patients did not experience improvement in cognition.

FDA sends response letter requesting studies to assess abuse-deterrent properties of oxycodone extended release.

HIV prevention dapivirine vaginal ring demonstrated reduced risk among teen girls.

In 2013, it was estimated that because of biosimilars, the US could save $250 billion throughout the next 10 years.

Actemra/RoActemra has potential to change how GCA is treated.

Scientists prepare to test first of its kind trispecific antibody in people.

More than 80% of patients receiving Tremfya demonstrated PASI 90 scores at week 100.

Trispecific antibodies show exceptionally promising results against HIV.

Alnylam Therapeutics expects to file for a New Drug Application in late 2017.

While HRT has been in and out of favor, for the right patient, hormone therapy is safe and effective.

The ongoing phase 3 trial has been selected for accelerated approval pathways in the US and Europe.

It is the first and only single oral dose drug approved for the most common gynecologic infection.

AbbVie filed for elagolix approval to treat endometriosis-associated pain, and current studies are testing the same drug effectiveness for uterine fibroids.

If approved, the drug could open a new line of treatment for people struggling to control symptoms despite drug therapy.

The long-term study shows biosimilar adalimumab, if approved, will further improve access to treatment for immunological diseases.